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Abstract
Whilst some populations have recently experienced dramatic declines in malaria, the majority of those most at risk
of Plasmodium falciparum malaria still lack access to effective treatment with artemisinin combination therapy (ACT)
and others are already facing parasites resistant to artemisinins.
In this context, there is a crucial need to improve both access to and targeting of ACT through greater availability
of good quality ACT and parasitological diagnosis. This is an issue of increasing urgency notably in the private
commercial sector, which, in many countries, plays an important role in the provision of malaria treatment. The
Affordable Medicines Facility for malaria (AMFm) is a recent initiative that aims to increase the provision of
affordable ACT in public, private and NGO sectors through a manufacturer-level subsidy. However, to date, there is
little documented experience in the programmatic implementation of subsidized ACT in the private sector.
Cambodia is in the unique position of having more than 10 years of experience not only in implementing
subsidized ACT, but also rapid diagnostic tests (RDT) as part of a nationwide social marketing programme. The
programme includes behaviour change communication and the training of private providers as well as the sale
and distribution of Malarine, the recommended ACT, and Malacheck, the RDT. This paper describes and evaluates
this experience by drawing on the results of household and provider surveys conducted since the start of the
programme.
The available evidence suggests that providers’ and consumers’ awareness of Malarine increased rapidly, but that of
Malacheck much less so. In addition, improvements in ACT and RDT availability and uptake were relatively slow,
particularly in more remote areas.
The lack of standardization in the survey methods and the gaps in the data highlight the importance of
establishing a clear system for monitoring and evaluation for similar initiatives. Despite these limitations, a number
of important lessons can still be learnt. These include the importance of a comprehensive communications strategy
and of a sustained and reliable supply of products, with attention to the geographical reach of both. Other
important challenges relate to the difficulty in incentivising providers and consumers not only to choose the
recommended drug, but to precede this with a confirmatory blood test and ensure that providers adhere to the
test results and patients to the treatment regime. In Cambodia, this is particularly complicated due to problems
inherent to the drug itself and the emergence of artemisinin resistance.
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Background
The importance of the private sector in the provision of
malaria treatment is widely recognized [1-10]. It is how-
ever only recently that its potential role in increasing
community access to good quality malaria treatment,
through artemisinin combination therapy (ACT) and
potentially parasitological diagnosis has been considered.
One response has been the Affordable Medicines Facility
for malaria (AMFm) initiative, the first phase of which is
being rolled out in eight countries. The AMFm aims to
increase access to ACT by lowering the cost of the drugs
through a manufacturer-level subsidy. In the selected
countries, public, private and not-for-profit first-line
buyers will be able to purchase nationally-recommended
ACT from manufacturers at around US$0.05 per dose, a
fraction of their actual cost. In the private sector, it is
anticipated that the saving will pass through the distribu-
tion chain, so that consumers will be able to purchase
ACT at a price comparable to that of older less effective
monotherapies (i.e. approximately $0.20 for an adult
course) [11]. To date, although there has been a number
of pilot studies [12-14], there is little documentation on
subsidizing ACT at a programmatic level on which to
base this roll-out [13-15].
There is even less information about subsidizing parasi-
tological diagnosis using Rapid Diagnostic Tests (RDTs)
in the private sector. This issue has recently come to the
fore as a number of countries report dramatic reductions
in malaria, and the importance of targeting ACT to those
with confirmed malaria has become more apparent. This
is reflected in the recently published World Health Orga-
nization (WHO) malaria treatment guidelines which now
recommend parasitological confirmation prior treatment
[16]. The availability of easy-to-use and quality-assured
RDTs for malaria [17] means that parasitological confir-
mation is no longer limited to public health facilities with
the capacity to perform microscopy, but can also poten-
tially be offered by community health workers and pri-
vate providers.
Cambodia is in the unique position of having had a
nationwide social marketing programme for both RDTs
and ACT in the private sector since 2002. As other coun-
tries prepare for the AMFm pilot, much could be learnt
from the Cambodian experience. However to date the
amount of information available has been limited[15]. The
aim of this paper is therefore to describe the development
and implementation of Cambodia’s social marketing pro-
gramme and to review the available evidence on the evolu-
tion of the programme’s outcomes in terms of product
awareness, availability, access, cost and quality.
Study population
Cambodia has a population of 13.7 million inhabitants,
of which 80% are rural [18] and 40% live with less than
US$1.25 per day [19]. Malaria transmission is micro-het-
erogenous, but generally limited to the relatively sparsely
populated hilly and forested areas mainly around the
country borders (Figure 1). An estimated three million
people are at risk of malaria, of which 1.6 million are
considered at high risk because they live within 1 km of
the forest, where the local vectors breed [20]. Unlike in
much of Africa, it is adults, who work and stay over-
night in the forest, who carry the highest burden of the
disease. Based on official statistics there has been a
downward trend in morbidity in the last decade, with
83,777 outpatient and 4,045 inpatient cases reported in
2009. Overall, malaria is reported to account for 0.6% of
outpatient cases and 3.5% of inpatient cases [21]. How-
ever, as around 80% of medical treatments are obtained
in the private sector [22,23], information from the offi-
cial Health Information System significantly underesti-
mates the true burden of disease.
The epidemiology of malaria differs remarkably across
the country. In the Northeast, malaria transmission is rela-
tively high, with reported annual incidence of 11 to 50 per
1,000 habitants [24], Plasmodium falciparum predomi-
nates and remains relatively drug-sensitive. By contrast,
along the Western border with Thailand, which is known
as the epicenter of multi-drug resistant P. falciparum
malaria [25,26], transmission is generally lower and Plas-
modium vivax predominates in some parts.
In 2000, Cambodia became the first country to switch its
first-line national malaria treatment policy for P. falci-
parum malaria to an ACT of artesunate and mefloquine
(ASMQ) [27]. The policy change was accompanied by a
number of innovative strategies aimed at increasing free or
affordable access to early diagnosis and good-quality treat-
ment and decreasing the use of inappropriate, sub-
standard and fake drugs. Artesunate and mefloquine were
co-blistered into age-specific packs named “A+M4”,
“A+M3” and “A+M2” for provision in public health facil-
ities. Parasitological diagnosis was promoted through the
introduction of RDTs and the strengthening of capacity
for skilled microscopy. In addition, a cadre of community
health workers known as Village Malaria Workers
(VMWs) were trained to provide free diagnosis and treat-
ment with RDTs and ACT in the most remote and at-risk
communities [28,29]. Finally, in recognition of the impor-
tance of the private sector, a “social marketing” pro-
gramme of subsidized co-blistered ASMQ and RDTs was
initiated in order to improve the availability and quality of
malaria diagnosis and treatment in this sector [30,31].
Social marketing is a relatively common approach for
increasing coverage of health services and products in
resource limited settings using the tools and concepts of
commercial marketing, including promotional activities,
branding, pre-packaging and subsidy of public health com-
modities [32,33].
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Case description: social marketing of RDTs and ACT
The development and pilot phase (1999-2001)
The social marketing programme was initiated by the Eur-
opean Commission Cambodia Malaria Control Project
(EC-CMCP) in partnership with the National Centre for
Parasitology, Entomology, and Malaria Control (CNM)
and the WHO. The programme started in 1999 with a
“pre-pilot” study during which packaging and promotional
materials, guidelines for community health providers,
wholesale and retail price levels and methods for monitor-
ing and evaluations were developed and pre-tested in one
community. The brand name Malarine was chosen for the
ACT, with the “M” in Malarine designed to look like three
“1’s” in order to encourage adherence to the once daily 3-
day regime (Figure 2). The drugs, artesunate and meflo-
quine were procured by the programme. Co-blistering and
packaging was undertaken locally in a specially renovated
blistering packaging facility with the support of the WHO.
For diagnosis, Paracheck®, the Histidine Rich Protein 2-
based P. falciparum-specific RDT used in the public sec-
tor, was branded as Malacheck for sale in the private
sector.
In 2000, a pilot study was conducted in two districts,
one in Battambang province in the Northwest of the
country and the other in Kampot province in the South
of the country. The pilot involved six wholesalers and
30 health providers [34] and, in addition to the provi-
sion of pre-packaged ACT and RDTs, a comprehensive
programme of Information, Education and Communica-
tion (IEC), training and support to both private drug
providers and public health workers was implemented.
An evaluation of the pilot found that that the “observed
result [was] promising” and resulted in plans to scale-up
[35].
Scale up and handover to Population Services
International (2002-2003)
In March 2002, the nationwide social marketing project
was officially launched, targeting the 17 malaria endemic
provinces. A single company was contracted to handle the
distribution of the products and an advertising agency was
used to develop a nationwide promotional campaign.
Then followed a transitional period with the EC-CMCP
closing at the end of the year, and the management of the
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programme being handed over to Population Services
International (PSI) in February 2003.
The Nationwide Social Marketing Programme (2004 to
present)
Since handover, PSI have continued to run the programme
and are responsible for all aspects including procurement,
packaging, sales and distribution of Malarine and Mala-
check; training of private providers; and behaviour change
communications. Financial support is provided by the
Global Fund to Fight AIDS, Tuberculosis and Malaria
(GFATM).
The products
Until 2007, artesunate and mefloquine were procured by
PSI from Mepha Pharma Ltd (for mefloquine 250 mg) and
Guilin Pharmaceutical Co. Ltd (for artesunate 250 mg and
50 mg), and were then locally co-blistered and packaged
in two age-specific packs: “Adult” for ages over 13 years
(weight > 30 kg) and “Child” for ages 6-13 years (weight
Figure 2 Malarine for Adult (2008).
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15-30 kg). The local co-blistering and packaging arrange-
ments became increasingly problematic due to issues
related to GFATM procurement procedures and the ambi-
guity over whether the local packaging facility had
achieved the necessary “Good Manufacturing Practice”
status to allow procurement using GFATM funds. Delays
have also been compounded by the repeatedly dashed
expectations of the country being able to switch to an
effective co-formulated single tablet combination ACT,
such as dihydroartemisinin-piperaquine. In both public
and private sectors, these problems resulted in severe pro-
curement delays and stock-outs [36] with packaging finally
being contracted out to Cipla Ltd in 2009. At the same
time, in line with changes in the national malaria treat-
ment guidelines, the dosing of Malarine for Adult was
increased and the age banding changed from over 13 years
to over 15 years, and an additional adolescent-age pack
was introduced for ages 11 to 15 years.
As for the RDT, this continued to be the Paracheck®
product, branded as “Malacheck” until 2009-2010. Since
then, in line with changes in the national guidelines, the
RDT was switched to a “combination” HRP2/pLDH RDT
that diagnoses both P. falciparum and non-P. falciparum
malaria, and is still marketed under the brand name
Malacheck.
Distribution
Malarine and Malacheck are stored initially in PSI’s ware-
house in Phnom Penh. Stocks for around two months are
then distributed to three regional depots from where PSI
sales representatives get their supply and distribute to
approximately 350 providers per month, mostly located
in provincial and district towns. Larger outlets then act
as de-facto wholesalers and serve less accessible providers
who may also buy from one another [37].
Cost and pricing
Since the beginning, there has been a recommended
retail price (RRP) at which retailers were supposed to sell
the products to the end-user. For Malarine (but not
Malacheck), the RRP has been printed on the boxes of
Malarine, for increased consumer awareness and to
encourage provider adherence. Under the EC-CMCP
pilot, the RRP for Malarine Adult was 7,900 riel (US
$1.93), for Malarine Child 4,900 riel ($1.20), and for
Malacheck 1,000 riel (US$0.24). After handover, PSI con-
ducted a willingness-to-pay survey and as a result
reduced the RRP of Malarine to 2,500 riel (US$ 0.61) for
both the adult and child packages [38]. In 2009, the
changes in the dosing regimen, age-banding and packa-
ging were accompanied by a halving of the RRP of the
“Child” dose to 1,200 riel (US$0.29) and the pricing of
the new “Adolescent” dose being set at 1,700 Riel (US
$0.41), with no change to the RRP for the “Adult” dose.
Prior to 2009, the cost to PSI of procuring Malarine
was US$ 3.11 for the adult blister and US$2.10 for the
child blister, including the costs of the drugs, packaging,
sampling and testing, freight, packing, insurance, and
delivery to the PSI warehouse. In 2009, the changes in
dosing and in the packaging facility were associated with
an increase in procurement prices to US$3.63 for the
adult dose, US$2.34 for the adolescent dose and $1.82 for
the child dose (personal communication, PSI Cambodia
procurement department). For the RDTs, the procure-
ment cost of the P. falciparum specific RDT was around
US$ 0.45 per test compared to around $0.59 for the com-
bination LDH/HRP2 test (personal communication, PSI
Cambodia procurement department).
Until 2009, in order to allow for a minimum distribution
margin of US$0.15 or around 33% per pack, PSI had a dif-
ferential pricing policy at which they sold products to
wholesalers compared to retailers. For wholesalers, Malar-
ine Adult was sold at US$5.00 for a dispenser of 12 packs
(equivalent to US$ 0.42 per pack) compared to US$5.50
(or US$ 0.46 per pack) direct to retailers. In 2009, this was
replaced by a single wholesale price. Thus, the price for
12-pack dispensers of Malarine for Adult, Adolescent and
Child were set at US$5.00 (US$0.42 per pack), US$3.20
(US$ 0.26 per pack) and US$2.20 (US$0.18 per pack)
respectively. For Malacheck, PSI originally sold boxes of
10 tests at a price of US$2.20 (US$0.22 per test). With an
RRP of US$ 0.24 per test this allowed for a distribution
margin of 9%. In 2009, in order to encourage providers to
always test before treatment, the wholesale price was
dropped to only US$0.50 for 10 tests (US$ 0.05 per test),
allowing retailers to increase their margin per test dramati-
cally, from 9% to 380% (Additional File 1).
Behaviour change communications
Behaviour change communication (BCC) has been a key
component on the social marketing strategy since its start
and has evolved over time. The aim of the programme is
to influence the behaviour of providers and consumers by
developing and delivering key messages through a range of
media. PSI put an emphasis on using evidence to develop
key messages and to evaluate the effectiveness of the BCC
programme. The range of media includes mass media
advertisements through television and radio spots, com-
munity educational activities through mobile video units,
distribution of point-of-sale materials such as posters and
job aids, training of providers and a “medical detailing”
programme. Private providers are trained on malaria diag-
nosis and treatment during one-day group sessions. Treat-
ment providers are also visited by medically or pharmacy
trained “ detailers” who provide additional advice and
support.
In the early years, the BCC materials focused on pro-
moting Malarine with increasing emphasis being placed
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on diagnosis in later years. The strategy differs between
providers and consumers with Malacheck actively being
promoted to providers, whilst parasitological diagnosis
(including microscopy) in general rather than Malacheck
specifically, is promoted amongst consumers.
Sales of Malarine and Malacheck
Data on retail sales to end-users are not currently avail-
able. However, an overview of PSI’s wholesale sales
records suggests that although the general trend has been
up, the sales of ACT and RDTs have fluctuated markedly
both in absolute terms and in relation to each other, par-
ticularly between 2006 and 2008 (Figure 3). This is likely
to be due to supply bottlenecks related to procurement
problems and in this context the fluctuation of sales
volumes cannot be interpreted as reflecting changes in
consumer demand. In 2009, seven years after the start of
the programme, wholesale sales of Malarine across all
age groups and Malacheck reached their highest levels.
The larger number of adult doses sold compared to child
and adolescent doses reflects the relatively higher disease
burden that falls on adults. Overall, PSI’s sales of Malar-
ine exceeded the number of doses of “A+M” provided
through public health facilities and through VMWs[15].
However, as there are no data linking Malarine sales
volumes to its use or to results of diagnostic testing it is
not possible to say what proportion of the doses sold in
the private sector were “appropriate”.
Discussion and evaluation
To date, there has been no formal evaluation of the
social marketing programme. However, there have been
a number of studies on the provision and utilization of
blood testing and anti-malarials in Cambodia (Addi-
tional File 2): six surveys provided data on providers’
knowledge of RDTs and ACT, product availability, sales
and/or selling prices and five others on consumers’
awareness of RDTs and ACT, access to confirmed diag-
nosis and quality treatment and costs. A brief overview
of the evolution of key quantitative outcomes of the
social marketing programme in terms of ACT and
RDTs awareness, availability, price and use is provided
in two accompanying files (Additional File 3 and Addi-
tional File 4).
Whilst these quantitative studies are not all nationally
representative and differ in terms of sample sizes, meth-
odologies and geographical areas covered (Additional
File 5), they provide valuable insights into the “Cambo-
dian experience” in improving RDTs and ACT aware-
ness, availability, access, prices, quality and patient
adherence.
Drugs
Awareness of the recommended ACT
Data on awareness of recommended ACT were available
from five household and/or provider surveys. During the
first year of scale-up, a quarter (24%) of respondents had
reportedly heard of Malarine, of which 79% said they had
heard about it from the television [39]. During the same
survey, around a quarter of private providers reportedly
recommended to their clients the nationally recom-
mended blister-packed ACT, that is either Malarine or
the public sector “A+M” [39]. Two years later, awareness
rates were higher: of 3,363 households and 123 providers
surveyed, 47% and 75% respectively reported that they
had heard of either Malarine or A+M [40]. By 2007,
awareness had risen further to 72% of surveyed house-
holds and 98% of surveyed providers respectively for
Malarine alone [41]. In the same year, however, a smaller
survey found that only 79% of 750 private providers had
Figure 3 PSI’s annual sales of Malarine and Malacheck® since the start of the programme. This Figure shows the evolution of PSI’s annual
sales volumes for Malarine and Malacheck® since the start of the nationwide programme.
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reportedly known of Malarine, and 63% reported it to be
the most effective treatment for P. falciparum malaria
[42]. More recently, of 180 private providers surveyed in
Western Cambodia, nearly all (98%) reported they had
heard of Malarine [43].
Availability of the recommended ACT
Several provider surveys measured the relative availability
of the recommended ACT compared to artemisinin
monotherapy (AMT) and other drugs in private commer-
cial outlets. In 2002, the first year of scale-up, unsurpris-
ingly, ACT availability was low, especially in more
remote areas, with none of the 107 village shops surveyed
stocking Malarine and only 40% of the 49 market-based
providers doing so [39]. Public sector “A+M” was avail-
able in around 30% of market-based providers and 8% of
village outlets, suggesting leakage of the drugs from the
public sector [39]. Artesunate monotherapies, on the
other hand, were more widely available in as many as
85% of market-based providers and 70% of village shops
[39]. Quinine, both in oral and injectable forms, and
chloroquine tablets were also widely stocked [39]. In
2004, availability of the recommended ACT remained
low: of 123 private providers interviewed, only 22%
reported stocking Malarine for Adult and only 5% Malar-
ine for Child. Public sector “A+M” was still available at
15% of private outlets and, as in 2002, AMT, quinine and
chloroquine continued to be the most widely available
anti-malarial drugs, and were stocked by 45%, 48% and
57% of all providers respectively [40].
By 2007, availability had increased, although the two
surveys conducted in this year provide different esti-
mates. In a survey conducted by PSI based on LQAS
methodology, only about half of communes in high-risk
areas had Malarine available with only 44% and 17% of
the 249 providers surveyed reported generally stocking
Malarine Adult and Malarine Child, respectively [44].
Penetration rates were particularly low for mobile provi-
ders, a popular source of treatment in rural areas. PSI
was actually experiencing stock outs of Malarine and,
without surprise, the majority of private providers
reported at least one day without any Malarine in stock
during the three months preceding the survey. Artesu-
nate continued to be stocked in 19% of outlets [44]. On
the other hand, the Cambodia national survey reported
better availability with around 63% of the 131 providers
interviewed reporting that they ‘usually’ stocked Malarine
for Adult and 44% Malarine for Child [41]. Public sector
“A+M” availability seemed to have decreased, with less
than 8% of providers reporting generally stocking it [41].
However, in this study, AMT remained widely available
with 41% of providers reporting they commonly stocked
artesunate tablets and 18% artesunate injection[41].
By 2009 Malarine was found to be the most frequently
stocked anti-malarial treatment [43]. However, the
popularity of AMTs amongst some providers still pre-
vailed, despite having been banned a year before and of
180 private providers interviewed, 58% stocked artemisi-
nin-based drugs, including artesunate tablets and inject-
able artesunate and artemether [43].
Uptake of the recommended ACT
In this paper, “uptake” refers to providers’ reported sell-
ing practices and households reported buying practices
for recommended blister-packed ACT and other anti-
malarial drugs. Before the nationwide scale-up in 2002,
361 household respondents who were interviewed on
anti-malarial drug use reported the widespread use of
“cocktails”, which usually consisted of a mix of three or
more types of tablets or capsules sold in little plastic
bags [28] (Figure 4). By contrast, only 8% reported
receiving the recommended blister-packed ACT [28].
Overall, 40% of all anti-malarial treatments received, or
78% of those that contained artemisinin, contained an
artemisinin derivative as a monotherapy[28]. The results
were corroborated by a larger study later that year, in
which out of 1,277 household respondents, blister packed
ASMQ accounted for less than 10% of all treatments
received and the most commonly received treatments
included AMTs and quinine [39]. Given the low levels of
availability particularly amongst rural providers, it is not
surprising that uptake remained low for several years with
the use of inappropriate treatment prevailing. In 2004, the
most commonly received treatment was reported to be
either “drug cocktails” or “unknown”[40] and, in 2006, of
150 respondents who received treatment, only 13%
reported receiving Malarine [36]. This was corroborated
one year later [42,44] with, for example, only 28% of 750
providers who reported they frequently provided prepack-
aged ACT to patients with P. falciparum malaria [42].
More recent data from studies including those conducted
by the ACTwatch Group and the ACT Consortium sug-
gest that uptake has improved since then.
Parasitological diagnosis and RDTs
Compared to treatment, there is, unfortunately, much
less information on awareness, perceptions and use of
RDTs. The available data are summarized and discussed
below.
Awareness and perception of RDTs
Before 2006, there is limited evidence on awareness of
RDTs or reported perceptions towards diagnosis. In 2006,
a study conducted by PSI, which used a Lickert scale to
elicit communities’ perceptions, reported that blood test-
ing was perceived to be a common practice if malaria
infection was suspected and that diagnosis blood tests in
general were neither considered a ‘waste or money’ nor a
‘waste of time’ [36]. Also, nearly 70% of respondents
reported that malaria could not be diagnosed without a
blood test, although only around half perceived RDTs to
be as reliable as microscopes[36]. On the providers’ side,
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nearly 88% of respondents knew that malaria symptoms
could be associated with other diseases but around a third
reported that malaria infection could be confirmed with-
out a blood test [42].
Availability of RDTs
In 2002, biological testing was found to be rarely avail-
able. Of 156 private providers, microscopy was reportedly
offered by 18% of market-based outlets and 21% of village
outlets and only 14% and 7% reportedly stocked RDTs
respectively [39]. This situation appears to have remained
unchanged for a number of years, with just over 10% of
outlets reportedly stocking Malacheck in 2004 and just
under 15% the public-sector version, Paracheck® [40],
suggesting some leakage. By 2007, Malacheck availability
was reported to have increased [41,44]: of 131 private
providers surveyed, nearly half (49%) reportedly stocked
it, whilst 15% continued to stock Paracheck® [41]. Over-
all, the pattern of Malacheck availability was noted to be
similar to that of Malarine®, with most pharmacies,
cabinets and drug stores selling the product, but less so
by mobile providers [44].
Use of RDTs
In the community studies on anti-malarial drug usage
conducted in 2002, only around 18% of patients with
recent malaria symptoms reported receiving a biological
diagnosis with a minority (15%) of tests having been
conducted using RDT[28]. Unsurprisingly, given the
lack of increase in availability, there was little change
over the next few years: in 2004, less than 15% of house-
holds who had sought care for malaria symptoms
reportedly received a blood test [40]. In 2007, this pro-
portion remained only 21%, although the proportion
being tested by RDT had reportedly increased to 61%
[41]. These estimates were somewhat in contrast with
another household study during 2006 in which 71% of
those who had symptoms and sought care in the last 12
months reportedly received a diagnostic test. Out of the
109 respondents who reported having a test, two-thirds
Figure 4 Drug “cocktails”. An assortment of mixed drug “cocktails”, which are a mix of several different types of drugs sold in little plastic
bags, often used for treating fever in Cambodia [28].
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were reportedly by RDT and nearly all (98%) were
reportedly positive, suggesting either inaccuracies in
interpreting the test or significant bias in the responses
[36]. On the supply side, of 110 providers interviewed,
85% reported they planned to provide a diagnostic test
to the next patient with malaria symptoms and a similar
proportion reported that they provided a test to their
last malaria patient. However, only 10% of providers
who reported they had treated malaria in the previous
six months indicated that they always provided a diag-
nosis [36].
It would be of interest to explore the relationship
between the use of RDTs, the result of the tests and the
sale of ACT. Unfortunately, the available data do not
allow for such analysis. However, some observations on
the sales of RDTs relative to that of ACT can be made
from the overall sales data presented in Figure 4.
Although the ratio of sales has varied from year to year,
the ratio has overall been close to one-to-one, except in
2007 when there was an acute shortage Malarine. PSI are
currently collecting and re-reading used RDTs from pri-
vate providers and preliminary findings suggest a positiv-
ity rate of around 30%, similar to that reported by village
malaria workers (personal communication, PSI Cambo-
dia malaria programme). The relatively high sales of
Malarine relative to Malacheck support the observation
that it is not uncommon for ACT to be sold without bio-
logical confirmation. However the difference may also be
in part because of private providers confirming infection
through microscopy rather than RDTs, as found recently
in Western Cambodia, where of the private providers
who reportedly tested patients’ blood before selling anti-
malarials 54% reported using microscopy only, 37% either
microscopy or RDTs and 19% RDTs only [43].
Cost and adherence to recommended pricing
Since the start of the programme, there have been recom-
mended wholesale and retail prices for each product.
However the available evidence suggests that adherence to
these recommendations has been variable. During the first
year of scale-up, households who had bought pre-packed
ACT at private outlets reported buying the drugs at close
to the recommended price of 7,900 riel, with a median of
8,000 riel (US$2). This compared to a median of 6,000 riel
(US$1.46) for other anti-malarials [39]. In 2004, when the
RRP for Malarine was still 7,900 riel, the national malaria
survey reported that the median price paid by consumers
for Malarine had reportedly fallen dramatically to 3,000
riel (US$0.73) [40]. In the same survey repeated in 2007,
by which time the RRP had been reduced to US$ 0.61
[44], the median price paid was still 3,500 riel (US$0.85)
[41]. However, results from a PSI study that same year,
reported much higher prices being paid: Malarine for
Adult, at a mean price of US$1.07 (range US$0.63-US
$3.75) and Malarine for Child at US$0.95 (range US$0.63-
US$2.50). This situation may however not come as a sur-
prise in the context of supply shortages due to procure-
ment difficulties. Furthermore, at the time retailers
reportedly purchased Malarine at a mean price of around
US$7.50 (range US$5.00-US$20.00) for 12 packs, well
above the PSI’s wholesale recommended price of $5.50 for
12 packs [44], and relatively close to the RRP, therefore,
squeezing retailers’ expected margins. This situation
shows the important influence that the distribution chain
is likely to have on retail outcomes, and highlights the lim-
ited information available on providers’ business practices
and pricing behaviours [45].
Similarly, in 2007, Malacheck was reported to be sold
to end-users at an average price of US$0.35 (range US
$0.25-US$1.25), which was US$0.10 higher than PSI’s
RRP (US$0.25), with price adherence being apparently
lower in areas with the highest risk of malaria transmis-
sion [44]. As for the drugs, retailers reported paying on
average US$2.90 (range US$1.90 - US$12.5) for 10 tests,
which was US$0.70 above the wholesale recommended
price of US$2.20[44].
In 2009, Malacheck was reportedly being sold by retai-
lers for around US$0.50, or US$0.26 above the RRP[43].
Quality and adherence
Both the drugs and the RDTs that are procured for the
social marketing programme are quality assured products
and undergo quality testing prior to distribution. How-
ever, there is little information available on the quality of
the products after distribution or on how well they are
used. The 2007 MAP survey suggested that the quality of
coverage, as measured by the presence of expired stocks
and correct storage conditions was generally very good
[44]. However, it also found that almost one third of pri-
vate providers had sold Malarine tablets individually by
either removing or cutting tablets from the blister pack.
More recently, about18% of surveyed outlets reportedly
stocked expired anti-malarials[43]. There are no data on
the quality of RDTs - neither regarding the quality of the
tests themselves after they have been stored under nor-
mal conditions, nor on how well they are used in
practice.
There is also little information on patients’ adherence in
terms of completion of recommended treatment courses.
The studies of anti-malarial drug use in 2002 assessed
adherence based on the self-reported duration of treat-
ment with different anti-malarials. In all, 41.1% (95% CI
36.4, 45.7) of respondents had received anti-malarials for
inadequate treatment duration. For the recommended
pre-packaged ACT adherence was relatively better with
72-78% of patients who took it reportedly taking the treat-
ment for the recommended 3 days [28,39] although only
62% of patients reported completing the whole package
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[28]. Adherence was lowest with treatments that included
quinine, mefloquine, chloroquine and artemisinin mono-
therapies. When artesunate was taken alone and not as
part of a pre-packaged treatment, only 13-28% took it for
the recommended duration of 7 days[28]. By 2006, around
71% of 675 household respondents reportedly knew that
pre-packed malaria treatment was effective only if the
entire course was taken [36].
Conclusions
With the imminent roll-out of the AMFm pilot in
selected malaria-endemic countries, there has been
much discussion about its likely impact on the availabil-
ity, uptake and end-user price of ACT in the private
sector [46-48] and the potential role of RDTs [49,50].
ACT subsidy schemes have already been implemented
in a limited number of countries, generally at a smaller
scale (e.g district) [12,14,51-55]. These suggest that a
subsidy on ACT can rapidly increase ACT availability in
private outlets, decrease ACT consumer prices, increase
ACT uptake and decrease artemisinin monotherapy use,
although these effects may tend to benefit relatively
accessible populations rather than the more remote and
poorer communities. Whilst providing useful insights,
most of these initiatives have been pilot studies, whose
implementation benefited from intense support and
monitoring activities, and which were limited to ACT
only. Therefore to date there is no detailed information
on the outcomes of subsidy schemes for both ACT and
RDT that have been implemented at national level and
that could guide the scale-up of ACT and introduction
of RDTs.
Cambodia is the first and only country with a mature
nation-wide social marketing programme, not only of
subsidised ACT, but also of RDTs. In the absence of a
formal evaluation, this case study has drawn together the
available data on the impact of this national programme.
The approach taken has inherent limitations due the
variability between studies in terms of design, geographi-
cal areas covered and measured indicators. However, use-
ful lessons can be learnt for the AMFm and the
implementation and evaluation of similar nationwide
programmes of subsidised ACT and RDTs in the private
sector (Table 1).
In terms of evaluation, the limitations in this case
study highlight the need for a comprehensive framework
for evaluation [56] and the systematic collection of stan-
dardised indicators. In view of the original aims of a
high level subsidy for good-quality ACT[57], this should
include household level data on access to affordable
good-quality ACT and the relative availability of sub-
standard drugs and artemisinin monotherapies. This is
essential in order to inform timely and appropriate
modification to the implementation process. With
decreasing prevalence of malaria and the emergence of
artemisinin resistance in Cambodia, there is also
increasing urgency to monitor access to parasitological
diagnosis and the appropriate use of RDTs and ACT,
and to collect surveillance data from private providers.
As for programme implementation, it is evident that
after 10 years of social marketing, Malarine is widely
known and appears to be the most popular anti-malar-
ial. However, this has taken many years to achieve, and
there are lessons to be learnt from the process, as well
as the ongoing challenges.
The first lesson concerns product awareness. In order
for providers to stock and sell the recommended ACT and
RDTs and to encourage consumers to buy these products,
awareness of the products is clearly important. In Cambo-
dia, there was a relatively rapid increase in brand aware-
ness for the drug Malarine. Achieving this has required an
intense and sustained behaviour change communication
(BCC) strategy, which includes provider training, radio
and television advertisements, mobile community video
units and job aids. If similar levels of awareness are to be
achieved for subsidised ACT in countries rolling out the
AMFm, it is likely that similar campaigns will be required,
and adequate resources made available. Awareness of the
RDT, Malacheck remained lower than that of Malarine,
reflecting the difference in emphasis in the marketing of
the products. For other malaria-endemic countries who
are rolling out both RDTs and ACT, careful consideration
will need to be given to providing adequate consumer and
provider information and training on the role and use of
RDTs from the start of the programme.
The second lesson concerns product availability. The
data suggest that it took several years for Malarine and
Malacheck to become readily available, especially in rural
areas and particularly through mobile providers, a popular
source of treatment. They also suggest that the RRP for
both products was poorly adhered to. In part these finding
are explained by intermittent bottlenecks in procurement
and the resulting central stock-outs. This highlights the
importance of ensuring a reliable supply of goods, and the
need for far-reaching distribution networks to ensure
availability of effective treatment in the least accessible
areas. It also suggests that different strategies may be
needed to target different types of providers, for example
informal providers in rural areas versus trained formal
providers in market towns. Although the problems with
the procurement and supply of ACT and RDTs go some
way to explaining their slow uptake by providers and con-
sumers, there are a number of other factors that have con-
tributed. One important factor influencing the slow
uptake of Malarine is the product itself. The key elements
of marketing are sometimes referred to as the “4 Ps” - pro-
duct, price, place and promotion. In the case of Malarine,
the price seems competitive; the promotion is intense and
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targets both consumers and providers; and, the packaging
is attractive. In terms of place, PSI distributes to a wide
range of providers in market towns, relying on the existing
distribution chain to reach outlets operating at the periph-
ery. However, there have been challenges with the product
itself. In Cambodia, the individual components of Malar-
ine - artesunate and mefloquine - had been available for
several years prior to their introduction as a combination
therapy into national policy. There has been a common
perception that mefloquine causes unpleasant side effects,
whilst artesunate on its own is effective (which it is not,
unless taken for 7 days) and well-tolerated. Until the
recent ban on the artesunate monotherapy, there was little
incentive for consumers to buy a pack of Malarine instead
of a pack of artesunate. Even now, a patient can choose to
buy Malarine, but to take only the artesunate tablets. How
much this might contributes to the development of arte-
misinin resistance in Cambodia is unknown but is of great
concern, and highlights the potential negative conse-
quences of the severe delays in the introduction of co-for-
mulated ACT in Cambodia [58].
As for the ongoing challenges in increasing uptake of
RDTs, one important challenge is the complexity of the
message. The social marketing of subsidised RDTs and
ACT for malaria is different from that of other public
health commodities, such as bed nets, condoms or contra-
ceptives. In most of these cases, there is a simple goal - to
maximize sales, and a single message - “buy this product”.
For RDTs and ACT, it is more complicated because there
is more than one objective and more than one message.
The key objectives are to maximise the sales of ACT to
the specific population of patients with malaria, whilst
Table 1 Key lessons and implications for the implementation and evaluation of nationwide programmes of subsidised
ACT and RDTs in the private sector
Programme evaluation
Lessons learnt Implications
• Difficult to assess the impact of programme due to the lack of routine
monitoring with standardised indicators, especially at the household
level
• Need for routine monitoring and evaluation using standardised
indicators to measure impact on specific programme objectives,
particularly in more remote areas:
• Could not assess ACT uptake, appropriateness of ACT uptake, quality of
ACT and RDTs and how these products are used
• At the household level (in addition to the standard indicator of
access to prompt treatment of fevers)
○ Access to affordable, good quality parasitological diagnosis
prior to treatment with ACT
○ Adherence to ACT treatment regimen
○ Use of sub-standard drugs, in particular sub-standard
artemisinin drugs and artemisinin monotherapies
○ Median price paid for recommended ACT (compared to the
most popular anti-malarial)
• At drug outlet level (in addition to indicators of awareness,
availability and price)
○ Quality of RDTs and ACT under field conditions
○ Correct use and interpretation of RDTs by providers
○ Correct treatment regimen dispensed by providers
• Difficult to assess why things worked or did not work • Consider a comprehensive evaluation of the implementation process
using qualitative methods, in order to understand how implementation
can and should be improved
Programme implementation
Lessons learnt Implications
• A high level of brand awareness was achieved through an effective
behaviour change communication strategy about Malarine
• Awareness, availability and uptake of Malacheck was lower than for
Malarine
• Availability of both ACT and RDTs took years to pick up and was
particularly low in rural areas and with mobile providers. In part this is
explained by supply bottlenecks.
• Despite Malarine being available, actual uptake remained low
compared to other anti-malarial drugs. Problems with uptake likely to be
associated with community perceptions and expectations.
• Depending on the setting, significant additional resources may be
required to raise awareness and knowledge through IEC activities
• In order to ensure improved targeting of ACT to patients with malaria,
attention needs to be paid to biological testing in behaviour change
communications, and in the training and support of private providers.
This is particularly important in low transmission settings where the
majority of fevers are not due to malaria
• Need to monitor availability of products in remote areas and consider
interventions to improve reach
• Need to ensure reliable supply of products
• Need to consider different strategies for different types of providers i.e.
mobile providers in rural areas versus trained formal providers in market
towns
• Need to monitor actual use; if it remains limited, seek to understand
why and address the underlying problem(s) - which may require
consideration of changing the price, the product (eg switching from co-
blistered mefloquine and artesunate) or/and modifying the
communications strategy.
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minimising sales of anti-malarials to the non-target popu-
lations. There is therefore at least three other key mes-
sages: firstly, “if you are going to buy an anti-malarial, only
buy the recommended ACT"; secondly, “before you buy
an anti-malarial, get tested first"; and thirdly, “if you test
negative, don’t take an anti-malarial”. In addition, there
are a number of other important messages, including for
example the importance of adherence to the recom-
mended course and appropriate referral to the public
health facilities. Where non-falciparum malaria is com-
mon, as in Cambodia, the message gets even more
complicated.
The third lesson concerns product pricing. Although
unlikely to be sufficient on their own, financial incentives
can be used to help to achieve the desired provider and
consumer behaviors with regard to diagnosis and treat-
ment. In Cambodia, RDTs are now sold to retailers at
almost one-tenth the cost of the adult drug (US$0.05 ver-
sus US$0.42) and should theoretically allow retailers to
make a 380% gross profit (assuming they receive their sup-
plies from PSI directly), whilst the recommended retail
price of the RDT is less than half the cost of the adult
drug (US$0.24 versus US$0.61). Other countries consider-
ing the promotion of RDT use in the private sector will
need to consider the resources required to provide finan-
cial incentives to promote their uptake alongside sufficient
training and support of private providers.
In addition it is important to identify and address
other non-financial barriers to the uptake and appropri-
ate use of RDTs. One likely contributory factor for pro-
viders’ reluctance to use RDTs or trust their results is
the lack of clarity about what to do when the result is
negative. Although referral to a public health facility is
advised, in reality this rarely takes place. There is an
urgent need for simple algorithms, which guide the
management of treatment in the “RDT negative”
patients and better evidence on the aetiology of non-
malarial febrile illness on which to base such algorithms.
Finally, it is important to be clear of the role of the pri-
vate sector in malaria diagnosis and treatment in the con-
text of the health system as a whole. In Cambodia, and in
many other developing countries, the aspiration is to pro-
vide better access to good quality care through the public
sector. Cornerstones of this strategy may include strength-
ening the provision of care at public health facilities and
the provision of free diagnosis and treatment through
trained village volunteers.
Additional material
Additional file 1: Programmatic prices and margins for PSI’s socially
marketed ACT and RDT. Additional File 1 presents programmatic prices
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and/or RDT awareness, availability, use and price since the start of the
programme
Additional file 3: Overview of survey results on ACT awareness,
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findings on the evolution of ACT-related outcomes since the start of the
social marketing programme, in terms of ACT awareness, availability and
use from both provider and household surveys.
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availability and use. Additional File 4 provides an overview of the key
findings on the evolution of RDT-related outcomes since the start of the
social marketing programme, in terms of RDT awareness, availability and
use from both provider and household surveys.
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